Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Rigshospitalet. Part of our company strategy is focused on the discovery and development of novel radiopharmaceuticals for improved diagnose, risk-stratification and treatment monitoring in cancer diseases using PET imaging. Our current PET ligand discovery research program and our academic collaborations are focused on discovering and developing disease-specific PET ligands for multiple cancer indications. Another part of our strategy is to develop partnerships with larger pharmaceutical or biotechnology firms that improve our ability to move new PET ligands through the late stage clinical trials and to bring them into the marketplace.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Ole Maaloes Vej 3, Copenhagen,capital Region 2200,denmark
- Phone
- +45 22830160
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- curasight.com
- Keywords
- Biotechnology, PET imaging, Cancer imaging.
- HQ
- Copenhagen, Capital Region
Curasight Questions
Curasight's helpline number is +45 22830160
Curasight's website is curasight.com
Curasight's LinkedIn profile is https://dk.linkedin.com/company/curasight
Curasight has
7 employees.
View email and phone details for 7
employees at Curasight.
Curasight's industry is
Biotechnology Research
Curasight's top competitors are
Lundbeck,
Minerva Imaging,
Cell To Cure Aps,
Ascendis Pharma,
Cessatech A/s,
Fluoguide A/s (Nasdaq: Fluo),
Expres2ion Biotechnologies,
Evaxion A/s,
Cluster For Molecular Imaging,
Zealand Pharma.
Curasight's categories are Biotechnology Research
Curasight's founding year is 2013
